Nina S. Kjellson Sells 7,779 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the sale, the director now directly owns 447,857 shares in the company, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA opened at $15.80 on Thursday. The stock’s 50-day moving average is $15.38 and its two-hundred day moving average is $19.17. The company has a market cap of $799.48 million, a price-to-earnings ratio of -9.81 and a beta of 1.04. Tyra Biosciences, Inc. has a 1-year low of $12.34 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently modified their holdings of the company. Franklin Resources Inc. purchased a new stake in Tyra Biosciences during the 3rd quarter worth about $278,000. Valence8 US LP acquired a new stake in shares of Tyra Biosciences during the 3rd quarter worth about $310,000. SG Americas Securities LLC purchased a new stake in Tyra Biosciences during the third quarter worth approximately $311,000. The Manufacturers Life Insurance Company acquired a new position in Tyra Biosciences in the third quarter valued at approximately $333,000. Finally, HighVista Strategies LLC purchased a new position in Tyra Biosciences in the second quarter valued at approximately $257,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TYRA. UBS Group initiated coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Monday, January 13th. Wedbush reiterated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.